Lantern Pharma is trading at $1.62 (-5.26%), with no clear company-specific negative catalyst identified for September 18, 2026.
- The latest announcement is a September 23 webinar on Open-Medicine AI’s business model and roadmap.
- The webinar is forward-looking rather than an evident negative trigger.
- Broader markets are modestly lower, while biotechnology is stronger.